Janux Therapeutics, Inc.
JANX
$13.15
-$0.47-3.45%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 23.74% | -31.39% | 28.19% | -44.03% | -16.28% |
| Total Depreciation and Amortization | 0.21% | -6.59% | -7.39% | 4.24% | 1.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.92% | 35.51% | -23.17% | -11.22% | 94.98% |
| Change in Net Operating Assets | 260.72% | -146.75% | 74.27% | 826.74% | -49.57% |
| Cash from Operations | 56.78% | -122.01% | 46.01% | -39.88% | -1.79% |
| Capital Expenditure | -157.55% | -13.98% | 80.34% | -27.49% | -783.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -71.13% | 253.01% | 312.73% | 100.60% | -1,101.00% |
| Cash from Investing | -71.95% | 255.68% | 431.75% | 100.46% | -1,103.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 20.41% | 497.16% | -48.32% | 5.88% | -99.77% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Financing | 20.41% | 497.16% | -48.32% | 72.20% | -99.86% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -112.83% | 197.24% | 80.95% | 94.03% | -188.36% |